

# ACT Onco<sup>®</sup> + Report

PATIENT		
Name: 楊英茵		Patient ID: 15696374
Date of Birth: Jul 03, 1984		Gender: Female
Diagnosis: Chromophobe renal cell carcinoma		
ORDERING PHYSICIAN		
Name: 張延驊醫師		Tel: 886-228712121
Facility: 臺北榮總		
Address: 臺北市北投區石牌路二段 201 號		
SPECIMEN		
Specimen ID: S11170020A		Type: FFPE tissue
Collection site: Kidney		D/ID: NA
Date received: Jan 14, 2022	Lab ID: AA-22-00247	

## ABOUT ACT Onco<sup>®</sup>+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) ( $\leq 15$  nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 13 genes.

## SUMMARY FOR ACTIONABLE VARIANTS

### VARIANTS/BIOMARKERS WITH EVIDENCE OF CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Probable Effects in Patient's Cancer Type		Probable Sensitive in Other Cancer Types
	Sensitive	Resistant	
Not detected			

### VARIANTS/BIOMARKERS WITH POTENTIAL CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Possibly Sensitive	Possibly Resistant
NF1 V1146fs	Everolimus, Selumetinib, Trametinib	Afatinib, Erlotinib, Gefitinib, Lapatinib, Cetuximab, Trastuzumab, Vemurafenib

## Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criteria for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

# ACTOnco<sup>®</sup> + Report

## TESTING RESULTS

### VARIANT(S) WITH CLINICAL RELEVANCE

#### - Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Allele Frequency
NF1	V1146fs	61.7%

#### - Copy Number Alterations

Chromosome	Gene	Variation	Copy Number
Chr7	CARD11	Amplification	6*

\* Increased gene copy number was observed.

#### - Fusions

Fusion Gene & Exon	Transcript ID
No fusion gene detected in this sample	

#### - Immune Checkpoint Inhibitor (ICI) Related Biomarkers

Biomarker	Results
Tumor Mutational Burden (TMB)	1.2 muts/Mb
Microsatellite Instability (MSI)	Microsatellite stable (MSS)

#### Note:

- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 57% tumor purity.
- TMB was calculated by using the sequenced regions of ACTOnco<sup>®</sup> + to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at  $\geq 7.5$  mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is  $< 30\%$ .

# ACT Onco<sup>®</sup> + Report

## THERAPEUTIC IMPLICATIONS

### TARGETED THERAPIES

Genomic Alterations	Therapies	Effect
<b>Level 3B</b>		
<b>NF1</b> V1146fs	Selumetinib	<b>sensitive</b>
<b>Level 4</b>		
<b>NF1</b> V1146fs	Everolimus, Trametinib	<b>sensitive</b>
<b>NF1</b> V1146fs	Afatinib, Erlotinib, Gefitinib, Cetuximab, Lapatinib, Trastuzumab, Vemurafenib	<b>resistant</b>

Therapies associated with benefit or lack of benefit are based on biomarkers detected in this tumor and published evidence in professional guidelines or peer-reviewed journals.

Level	Description
<b>1</b>	FDA-recognized biomarkers predictive of response or resistance to FDA approved drugs in this indication
<b>2</b>	Standard care biomarkers (recommended by the NCCN guideline) predictive of response or resistance to FDA approved drugs in this indication
<b>3A</b>	Biomarkers predictive of response or resistance to therapies approved by the FDA or NCCN guideline in a different cancer type
<b>3B</b>	Biomarkers that serve as inclusion criteria for clinical trials (minimal supportive data required)
<b>4</b>	Biomarkers that show plausible therapeutic significance based on small studies, few case reports, or preclinical studies

# ACT Onco<sup>®</sup> + Report

## IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

### - Other Biomarkers with Potential Clinical Effects for ICIs

Genomic Alterations	Potential Clinical Effects
Not Detected	

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

## CHEMOTHERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to chemotherapies.

## HORMONAL THERAPIES

Genomic Alterations	Therapies	Effect	Level of Evidence	Cancer Type
<b>NF1</b> V1146fs	Tamoxifen	<b>Less sensitive</b>	Clinical	Breast cancer

## OTHERS

### Pharmacogenomic implication

Gene	Detection Site	Genotype	Drug Impact	Level of Evidence*
UGT1A1	rs4148323	AG	Irinotecan-based regimens	Level 1B

#### Clinical Interpretation:

Patients with the AG genotype and cancer who are treated with irinotecan-based regimens may have an increased risk of diarrhea and neutropenia as compared to patients with the GG genotype, or a decreased risk of diarrhea and neutropenia compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of diarrhea and neutropenia.

\* Level of evidence was defined by PharmGKB (<https://www.pharmgkb.org/page/clinAnnLevels>)

**Level 1A:** Clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation.

**Level 1B:** Clinical annotations describe variant-drug combinations with a high level of evidence supporting the association but no variant-specific prescribing guidance in an annotated clinical guideline or FDA drug label.

**Level 2A:** Variants in Level 2A clinical annotations are found in PharmGKB's Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely.

#### Note:

Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

# ACT Onco<sup>®</sup> + Report

## VARIANT INTERPRETATION

### NF1 V1146fs

#### Biological Impact

The neurofibromin 1 (NF1) gene encodes a GTPase activating protein (GAP) which is an important negative regulator of the Ras cellular proliferation pathways<sup>[1][2][3][4]</sup>. Besides, NF1 also physically interacts with the N-terminal domain of focal adhesion kinase (FAK) and involves in the regulation of cell adhesion, growth, and other pathways<sup>[5][6]</sup>. NF1 is considered a classical haploinsufficient tumor suppressor gene with loss of one allele through inherited or acquired mutation may lead to reduced protein expression and is insufficient to execute normal cellular functions contributing to tumor development<sup>[7][8][9][10][11]</sup>. NF1 syndrome is a germline condition resulting in a predisposition to several types of cancer such as neurofibromas, melanoma, lung cancer, ovarian cancer, breast cancer, colorectal cancer, hematological malignancies<sup>[12][13][14]</sup>. Meanwhile, sporadic NF1 mutations have been observed in multiple cancer types<sup>[15]</sup>, including myelodysplastic syndromes, melanomas, colon cancer<sup>[16]</sup>, glioblastomas<sup>[17]</sup>, lung cancer<sup>[18]</sup>, ovarian cancer, and breast cancer<sup>[12]</sup>.

V1146fs mutation results in a change in the amino acid sequence beginning at 1146, likely to cause premature truncation of the functional NF1 protein (UniProtKB). This mutation is predicted to lead to a loss of NF1 protein function, despite not being characterized in the literature.

#### Therapeutic and prognostic relevance

In April 2020, the U.S. FDA has approved selumetinib for pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

A phase II trial (NCT02664935, NLMT) demonstrated that selumetinib in combination with docetaxel resulted in a confirmed ORR of 28.5% (4/14), durable clinical benefit (DCB) rate of 50% (7/14), and mPFS of 5.3 months in lung adenocarcinoma patients harboring NF1 loss<sup>[19]</sup>.

NF1 loss has been determined as an inclusion criterion for the trials evaluating selumetinib efficacies in lung cancer (NCT02664935) and NF1-associated tumors (NCT03326388).

A case study had reported that MEK inhibitor, trametinib, was effective in a treatment-refractory neurofibromatosis type I-associated glioblastoma<sup>[20]</sup>. Various preclinical data had also supported the activity of MEK and mTOR inhibitors in NF1-deficient tumors<sup>[21][22][23][24][25][26]</sup>.

In an NGS-based study, patients harboring mutations in the mTOR pathway, including mTOR, TSC1, TSC2, NF1, PIK3CA, and PIK3CG responded to everolimus<sup>[27]</sup>.

NF1 depletion has been associated with drug resistance to RAF and EGFR inhibitors, tamoxifen, and retinoic acid<sup>[15][28]</sup>. For example, loss of NF1 was identified in patients with lung adenocarcinomas or colorectal cancer who presented resistance to anti-EGFR treatment, including erlotinib, gefitinib, afatinib, and cetuximab, respectively<sup>[29][30][31]</sup>. Notably, preclinical studies further revealed that the addition of a MEK inhibitor could restore the sensitivity to erlotinib<sup>[29]</sup>.

In a liquid biopsy-based ctDNA profiling study of HER2-positive metastatic gastric cancer, NF1 loss (either induced by mutation or deletion) was suggested as a novel mechanism contributes to trastuzumab resistance. The cell-based study also showed that the trastuzumab resistance could be overcome with a combination of HER2 and MEK/ERK inhibitors<sup>[32]</sup>.

Loss of NF1 in patients with BRAF-mutated melanomas was suggested conferring resistance to BRAF inhibitors<sup>[33][34][35][36]</sup>.

# ACT Onco<sup>®</sup> + Report

## CARD11 Amplification

### **Biological Impact**

CARD11 (caspase recruitment domain 11) gene encodes a cytoplasmic scaffold protein of the CARD11/BCL10/MALT1 (CBM) complex which plays essential roles in regulating apoptosis and NF-κB activation in response to upstream stimuli<sup>[37][38]</sup>. CARD11 gain-of-function mutations are frequently detected in human diffuse large B-cell lymphoma (DLBCL)<sup>[39]</sup> and cutaneous squamous cell carcinoma<sup>[40]</sup>. Moreover, CARD11 gene amplification has been observed in a significant proportion of DLBCL<sup>[41]</sup>. Biochemical assays revealed that enforced expression of CARD11/BCL10/MALT1 is essential for transformation of B-cell and survival of DLBCL cell<sup>[42]</sup>.

### **Therapeutic and prognostic relevance**

Retrospective studies have shown that high CARD11 expression or CARD11 gene amplification was associated with poor survival in diffuse large B cell lymphoma (DLBCL)<sup>[43][41]</sup>.

# ACT Onco® + Report

## US FDA-APPROVED DRUG(S)

### Everolimus (AFINITOR)

Everolimus, a derivative of sirolimus, works as an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) and blocks mTORC1-mediated downstream signals for cell growth, proliferation, and survival. Everolimus is developed and marketed by Novartis under the trade name AFINITOR.

### - FDA Approval Summary of Everolimus (AFINITOR)

<b>RADIANT-4</b> <sup>[44]</sup> NCT01524783	<b>Lung or gastrointestinal neuroendocrine tumor</b> (Approved on 2016/02/26)
	- Everolimus vs. Placebo [PFS(M): 11 vs. 3.9]
<b>BOLERO-2</b> <sup>[45]</sup> NCT00863655	<b>Breast cancer</b> (Approved on 2012/07/20)
	<b>ER+/HER2-</b> Everolimus + exemestane vs. Placebo + exemestane [PFS(M): 7.8 vs. 3.2]
<b>RADIANT-3</b> <sup>[46]</sup> NCT00510068	<b>Pancreatic neuroendocrine tumor</b> (Approved on 2011/05/05)
	- Everolimus vs. Placebo [PFS(M): 11 vs. 4.6]
<b>EXIST-1</b> <sup>[47]</sup> NCT00789828	<b>Subependymal giant cell astrocytoma</b> (Approved on 2010/10/29)
	- Everolimus vs. Placebo [ORR(%): 35.0]
<b>RECORD-1</b> <sup>[48]</sup> NCT00410124	<b>Renal cell carcinoma</b> (Approved on 2009/05/30)
	- Everolimus vs. Placebo [PFS(M): 4.9 vs. 1.9]

### Selumetinib (KOSELUGO)

Selumetinib is a kinase inhibitor. Selumetinib is developed and marketed by AstraZeneca under the trade name KOSELUGO.

### - FDA Approval Summary of Selumetinib (KOSELUGO)

<b>SPRINT</b> NCT01362803	<b>Plexiform neurofibromas</b> (Approved on 2020/04/10)
	<b>Neurofibromatosis type 1</b>
	Selumetinib [ORR(%): 66.0]



# ACT Onco® + Report

## Trametinib (MEKINIST)

Trametinib is an anti-cancer inhibitor which targets MEK1 and MEK2. Trametinib is developed and marketed by GlaxoSmithKline (GSK) under the trade name MEKINIST.

### - FDA Approval Summary of Trametinib (MEKINIST)

<b>BRF117019</b> <sup>[49]</sup> NCT02034110	<b>Anaplastic thyroid cancer</b> (Approved on 2018/05/04)
	<b>BRAF V600E</b> Dabrafenib + trametinib [ORR(%): 61.0]
<b>BRF113928</b> <sup>[50]</sup> NCT01336634	<b>Non-small cell lung cancer</b> (Approved on 2017/06/22)
	<b>BRAF V600E</b> Trametinib + dabrafenib vs. Dabrafenib [ORR(%): 63.0 vs. 27.0, DOR(M): 12.6 vs. 9.9]
<b>COMBI-d</b> <sup>[51]</sup> NCT01584648	<b>Melanoma</b> (Approved on 2014/01/10)
	<b>BRAF V600E/K</b> Trametinib + dabrafenib vs. Dabrafenib + placebo [PFS(M): 9.3 vs. 8.8]
<b>METRIC</b> <sup>[52]</sup> NCT01245062	<b>Melanoma</b> (Approved on 2013/05/29)
	<b>BRAF V600E/K</b> Trametinib vs. Dacarbazine or paclitaxel [PFS(M): 4.8 vs. 1.5]

D=day; W=week; M=month



# ACT Onco<sup>®</sup> + Report

## ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit <https://clinicaltrials.gov> to search and view for a complete list of open available and updated matched trials.

No trial has been found.

# ACT Onco<sup>®</sup> + Report


## SUPPLEMENTARY INFORMATION OF TESTING RESULTS DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

### - Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
NF1	V1146fs	26	c.3436del	NM_001042492	-	61.7%	209

### - Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



# ACT Onco<sup>®</sup> + Report

## OTHER DETECTED VARIANTS

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
HNF1A	D80V	1	c.239A>T	NM_000545	-	41.7%	139
KMT2C	T820I	14	c.2459C>T	NM_170606	COSM4606481	14.9%	1292
NSD1	Splice region	-	c.4642-7T>C	NM_022455	-	53.2%	664
RET	V292M	5	c.874G>A	NM_020975	COSM6381457	19.1%	141
USH2A	Splice region	-	c.6958-5C>T	NM_206933	-	21.1%	294
USH2A	V2228E	35	c.6683T>A	NM_206933	-	24.0%	608



### Note:

- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.

# ACT Onco<sup>®</sup> + Report

## TEST DETAILS

### SPECIMEN RECEIVED AND PATHOLOGY REVIEW



- Collection date: Jan 2022
- Facility retrieved: 臺北榮總
- H&E-stained section No.: S11170020A
- Collection site: Kidney
- Examined by: Dr. Pei-Yi Chu
- 1. The percentage of viable tumor cells in total cells in the whole slide (%): 65%
- 2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 90%
- 3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 0%
- 4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 0%
- 5. Additional comment: NA
- Manual macrodissection: Not performed
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

## RUN QC

- Panel: ACTOnco<sup>®</sup>+

### DNA test

- Mean Depth: 608x
- Target Base Coverage at 100x: 92%

### RNA test

- Total reads: 191545
- Average unique RNA Start Sites per control GSP2: 160

# ACT Onco<sup>®</sup> + Report

## LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage, .
3. This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

## NEXT-GENERATION SEQUENCING (NGS) METHODS

### DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (InDels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage  $\geq 25$ , allele frequency  $\geq 5\%$  and actionable variants with allele frequency  $\geq 2\%$  were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at  $100\times \geq 85\%$  with a mean coverage  $\geq 500\times$ .

Variants reported in Genome Aggregation database with  $> 1\%$  minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:

Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation  $\geq 0.3$  were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco<sup>®</sup>+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as "TMB-High", "TMB-Low" or "Cannot Be Determined". TMB-High corresponds to  $\geq 7.5$  mutations per megabase (Muts/Mb); TMB-Low corresponds to  $< 7.5$  Muts/Mb. TMB is reported as "Cannot Be Determined" if the tumor purity of the sample is  $< 30\%$ .

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in  $> 400$  genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

# ACT Onco<sup>®</sup> + Report

## RNA test

Extracted RNA was reverse-transcribed and subjected to library construction. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific). To ensure sequencing quality for fusion variant analysis, the average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) should be  $\geq 10$ .

The fusion analysis pipeline aligned sequenced reads to the human reference genome, identified regions that map to noncontiguous regions of the genome, applied filters to exclude probable false-positive events and, annotated previously characterized fusion events according to Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In general, samples with detectable fusions need to meet the following criteria: (1) Number of unique start sites (SS) for the GSP2  $\geq 3$ ; (2) Number of supporting reads spanning the fusion junction  $\geq 5$ ; (3) Percentage of supporting reads spanning the fusion junction  $\geq 10\%$ ; (4) Fusions annotated in Quiver Gene Fusion Database.

## DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

## Variant Analysis:

醫檢師張筑芃 博士  
Chu-Yuan Chang Ph.D.  
檢字第 020115 號



## Sign Off

醫檢師張筑芃 博士  
Chu-Yuan Chang Ph.D.  
檢字第 020115 號



# ACT Onco<sup>®</sup> + Report

## GENE LIST SNV & CNV

ABCB1*	ABCC2*	ABCG2*	ABL1	ABL2	ADAMTS1	ADAMTS13	ADAMTS15	ADAMTS16	ADAMTS18	ADAMTS6	ADAMTS9
ADAMTS11	ADGRA2	ADH1C*	AKT1	AKT2	AKT3	ALDH1A1*	ALK	AMER1	APC	AR	ARAF
ARID1A	ARID1B	ARID2	ASXL1	ATM	ATR	ATRX	AURKA	AURKB	AXIN1	AXIN2	AXL
B2M	BAP1	BARD1	BCL10	BCL2*	BCL2L1	BCL2L2*	BCL6	BCL9	BCOR	BIRC2	BIRC3
BLM	BMP1R1A	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2*	BTX	BUB1B	CALR
CANX	CARD11	CASP8	CBFB	CBL	CCNA1	CCNA	CCNB1	CCNB2	CCNB3	CCND1	CCND2
CCND3	CCNE1	CCNE2	CCNH	CD19	CD274	CD58	CD70*	CD79A	CD79B	CDC73	CDH1
CDK1	CDK12	CDK2	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDKN1A	CDKN1B	CDKN2A
CDKN2B	CDKN2C	CEBPA*	CHEK1	CHEK2	CIC	CREBBP	CRKL	CRLF2	CSF1R	CTCF	CTLA4
CTNNA1	CTNNB1	CUL3	CYLD	CYP1A1*	CYP2B6*	CYP2C19*	CYP2C8*	CYP2D6	CYP2E1*	CYP3A4*	CYP3A5*
DAXX	DCUN1D1	DDR2	DICER1	DNMT3A	DOT1L	DPYD	DTX1	E2F3	EGFR	EP300	EPCAM
EPHA2	EPHA3	EPHA5	EPHA7	EPHB1	ERBB2	ERBB3	ERBB4	ERCC1	ERCC2	ERCC3	ERCC4
ERCC5	ERG	ESR1	ESR2	ETV1	ETV4	EZH2	FAM46C	FANCA	FANCC	FANCD2	FANCE
FANCF	FANCG	FANCL	FAS	FAT1	FBXW7	FCGR2B	FGF1*	FGF10	FGF14	FGF19*	FGF23
FGF3	FGF4*	FGF6	FGFR1	FGFR2	FGFR3	FGFR4	FH	FLCN	FLT1	FLT3	FLT4
FOXL2*	FOXP1	FRG1	FUBP1	GATA1	GATA2	GATA3	GNA11	GNA13	GNAQ	GNAS	GREM1
GRIN2A	GSK3B	GSTP1*	GSTT1*	HGF	HIF1A	HIST1H1C*	HIST1H1E*	HNF1A	HR	HRAS*	HSP90AA1
HSP90AB1	HSPA4	HSPA5	IDH1	IDH2	IFNL3*	IGF1	IGF1R	IGF2	IKBKB	IKBKE	IKZF1
IL6	IL7R	INPP4B	INSR	IRF4	IRS1	IRS2*	JAK1	JAK2	JAK3	JUN*	KAT6A
KDM5A	KDM5C	KDM6A	KDR	KEAP1	KIT	KMT2A	KMT2C	KMT2D	KRAS	LCK	LIG1
LIG3	LMO1	LRP1B	LYN	MALT1	MAP2K1	MAP2K2	MAP2K4	MAP3K1	MAP3K7	MAPK1	MAPK3
MAX	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MET	MITF	MLH1	MPL	MRE11
MSH2	MSH6	MTHFR*	MTOR	MUC16	MUC4	MUC6	MUTYH	MYC	MYCL	MYCN	MYD88
NAT2*	NBN	NEFH	NF1	NF2	NFE2L2	NFKB1	NFKBIA	NKX2-1*	NOTCH1	NOTCH2	NOTCH3
NOTCH4	NPM1	NQO1*	NRAS	NSD1	NTRK1	NTRK2	NTRK3	PAK3	PALB2	PARP1	PAX5
PAX8	PBRM1	PDCD1	PDCD1LG2	PDGFRA	PDGFRB	PDIA3	PGF	PHOX2B*	PIK3C2B	PIK3C2G	PIK3C3
PIK3CA	PIK3CB	PIK3CD	PIK3CG	PIK3R1	PIK3R2	PIK3R3	PIM1	PMS1	PMS2	POLB	POLD1
POLE	PPARG	PPP2R1A	PRDM1	PRKAR1A	PRKCA	PRKCB	PRKCG	PRKCI	PRKCQ	PRKDC	PRKN
PSMB8	PSMB9	PSME1	PSME2	PSME3	PTCH1	PTEN	PTGS2	PTPN11	PTPRD	PTPRT	RAC1
RAD50	RAD51	RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	RECQL4
REL	RET	RHOA	RICTOR	RNF43	ROS1	RPPH1	RPTOR	RUNX1	RUNX1T1	RXRA	SDHA
SDHB	SDHC	SDHD	SERPINB3	SERPINB4	SETD2	SF3B1	SGK1	SH2D1A*	SLC19A1*	SLC22A2*	SLC1B1*
SLC1B3*	SMAD2	SMAD3	SMAD4	SMARCA4	SMARCB1	SMO	SOC1*	SOX2*	SOX9	SPEN	SPOP
SRC	STAG2	STAT3	STK11	SUFU	SYK	SYNE1	TAF1	TAP1	TAP2	TAPBP	TBX3
TEK	TERT	TET1	TET2	TGFBR2	TMSB4X*	TNF	TNFAIP3	TNFRSF14	TNFSF11	TOP1	TP53
TPMT*	TSC1	TSC2	TSHR	TYMS	U2AF1	UBE2A*	UBE2K	UBR5	UGT1A1*	USH2A	VDR*
VEGFA	VEGFB	VHL	WT1	XIAP	XPO1	XRCC2	ZNF217				

\*Analysis of copy number alterations NOT available.

## FUSION

ALK	BRAF	EGFR	FGFR1	FGFR2	FGFR3	MET	NRG1	NTRK1	NTRK2	NTRK3	RET	ROS1
-----	------	------	-------	-------	-------	-----	------	-------	-------	-------	-----	------




# ACT Onco<sup>®</sup> + Report

## APPENDIX

### POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION

Not Applicable.

### SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS



1: Everolimus; 2: Trametinib, Selumetinib

# ACT Onco<sup>®</sup> + Report

## DISCLAIMER

### 法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。

本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。

本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

### 醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

### 基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

### 證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

### 責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

# ACT Onco<sup>®</sup> + Report

## REFERENCE

1. PMID: 8563751; 1996, Nat Genet;12(2):144-8  
Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.
2. PMID: 1946382; 1991, Proc Natl Acad Sci U S A;88(21):9658-62  
Identification of the neurofibromatosis type 1 gene product.
3. PMID: 2116237; 1990, Cell;62(3):599-608  
The neurofibromatosis type 1 gene encodes a protein related to GAP.
4. PMID: 2121370; 1990, Cell;63(4):843-9  
The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21.
5. PMID: 14502561; 2003, J Cell Physiol;197(2):214-24  
NF1 modulates the effects of Ras oncogenes: evidence of other NF1 function besides its GAP activity.
6. PMID: 19479903; 2009, Mol Carcinog;48(11):1005-17  
Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase.
7. PMID: 28680740; 2017, Adv Med Biol;118():83-122  
Haploinsufficient tumor suppressor genes.
8. PMID: 10442636; 1999, Oncogene;18(31):4450-9  
Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation.
9. PMID: 16288202; 2006, Oncogene;25(16):2297-303  
NF1 haploinsufficiency augments angiogenesis.
10. PMID: 18089636; 2008, Hum Mol Genet;17(7):936-48  
Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1.
11. PMID: 7920653; 1994, Nat Genet;7(3):353-61  
Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.
12. PMID: 25026295; 2014, Oncotarget;5(15):5873-92  
The NF1 gene revisited - from bench to bedside.
13. PMID: 29892687; 2018, Gynecol Oncol Rep;23():41-44  
Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1.
14. PMID: 29926297; 2018, Breast Cancer Res Treat;171(3):719-735  
Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype.
15. PMID: 28637487; 2017, Hum Genomics;11(1):13  
The NF1 somatic mutational landscape in sporadic human cancers.
16. PMID: 15840687; 2005, Gut;54(8):1129-35  
NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer.
17. PMID: 20129251; 2010, Cancer Cell;17(1):98-110  
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
18. PMID: 27158780; 2016, Nat Genet;48(6):607-16  
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.
19. PMID: 32669708; 2020, Nature;583(7818):807-812

# ACT Onco<sup>®</sup> + Report

The National Lung Matrix Trial of personalized therapy in lung cancer.

20. PMID: 26936308; 2016, J Clin Pharm Ther;41(3):357-359  
Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma.
21. PMID: 22573716; 2012, Cancer Res;72(13):3350-9  
Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency.
22. PMID: 19727076; 2009, Nature;461(7262):411-4  
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.
23. PMID: 23858101; 2013, Mol Cancer Ther;12(9):1906-17  
NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.
24. PMID: 23221341; 2013, J Clin Invest;123(1):340-7  
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
25. PMID: 18483311; 2008, Mol Cancer Ther;7(5):1237-45  
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.
26. PMID: 23209032; 2013, Clin Cancer Res;19(2):450-61  
Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
27. PMID: 26859683; 2016, Oncotarget;7(9):10547-56  
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
28. PMID: 21482774; 2012, Proc Natl Acad Sci U S A;109(8):2730-5  
Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen.
29. PMID: 24535670; 2014, Cancer Discov;4(5):606-19  
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.
30. PMID: 29703253; 2018, BMC Cancer;18(1):479  
SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.
31. PMID: 30858928; 2019, Oncotarget;10(14):1440-1457  
CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition.
32. PMID: 30269082; 2019, Gut;68(7):1152-1161  
Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.
33. PMID: 24576830; 2014, Cancer Res;74(8):2340-50  
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
34. PMID: 23171796; 2013, Cancer Discov;3(3):338-49  
Elucidating distinct roles for NF1 in melanomagenesis.
35. PMID: 23288408; 2013, Cancer Discov;3(3):350-62  
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
36. PMID: 24265153; 2014, Cancer Discov;4(1):94-109  
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
37. PMID: 11278692; 2001, J Biol Chem;276(15):11877-82  
CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B.
38. PMID: 26260210; 2015, Mol Immunol;68(2 Pt C):546-57

# ACT Onco<sup>®</sup> + Report

TCR signaling to NF-κB and mTORC1: Expanding roles of the CARMA1 complex.

39. PMID: 18323416; 2008, Science;319(5870):1676-9  
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.
40. PMID: 26212909; 2015, Am J Pathol;185(9):2354-63  
Novel CARD11 Mutations in Human Cutaneous Squamous Cell Carcinoma Lead to Aberrant NF-κB Regulation.
41. PMID: 22397314; 2012, Leuk Lymphoma;53(10):1971-7  
Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.
42. PMID: 26668357; 2015, Proc Natl Acad Sci U S A;112(52):E7230-8  
Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
43. PMID: 26876250; 2016, Zhonghua Xue Ye Xue Za Zhi;37(1):30-4  
[Expression and prognostic value of CARD11 in diffuse large B cell lymphoma].
44. PMID: 26703889; 2016, Lancet;387(10022):968-977  
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
45. PMID: 22149876; 2012, N Engl J Med;366(6):520-9  
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
46. PMID: 21306238; 2011, N Engl J Med;364(6):514-23  
Everolimus for advanced pancreatic neuroendocrine tumors.
47. PMID: 23158522; 2013, Lancet;381(9861):125-32  
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
48. PMID: 18653228; 2008, Lancet;372(9637):449-56  
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
49. PMID: 29072975; 2018, J Clin Oncol;36(1):7-13  
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
50. PMID: 27080216; 2016, Lancet Oncol;17(5):642-50  
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
51. PMID: 25265492; 2014, N Engl J Med;371(20):1877-88  
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
52. PMID: 22663011; 2012, N Engl J Med;367(2):107-14  
Improved survival with MEK inhibition in BRAF-mutated melanoma.